Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CXCR2 | P25025 | 12/20 | 0.42 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.40 |
| ▸ | CX3CR1 | P49238 | 1/20 | 0.39 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.38 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.38 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6563192 | 0.94 | CXCR2 (0.51) | ALDH1A1TSHRCXCR2CX3CR1SIRT5 | |
| SCHEMBL6564159 | 0.93 | ALDH1A1 (0.52) | ALDH1A1TSHRCXCR2CXCR1CX3CR1 | |
| SCHEMBL6565711 | 0.83 | ALDH1A1 (0.56) | ALDH1A1TSHRCXCR2CXCR1HDAC4 | |
| SCHEMBL6563973 | 0.83 | CXCR2 (0.48) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL6564228 | 0.81 | CXCR2 (0.47) | CXCR2CXCR1CX3CR1 | |
| Hydrochloric Acid SCHEMBL6564293 | 0.80 | CXCR2 (0.47) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL6565740 | 0.80 | ALDH1A1 (0.55) | ALDH1A1TSHRSIRT5FOLH1CTSK | |
| SCHEMBL4588723 | 0.78 | CXCR2 (0.60) | CXCR2CXCR1CX3CR1 | |
| SCHEMBL7498490 | 0.78 | ALDH1A1 (0.49) | ALDH1A1TSHRHDAC4HDAC1SIRT5 | |
| SCHEMBL4586237 | 0.77 | CXCR2 (0.56) | CXCR2CXCR1CX3CR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1161232-B1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-03-24 | — | — | EP | claimed |
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-06-12 | — | — | US | claimed |
| US-6500863-B1 | INTERLEUKIN BINDING INHIBITORS SUCH AS N-(2-HYDROXYL-3-AMINO SULFONYL-4-CHLOROPHENYL)-N'-(2-BROMOPHENYL)UREA, USED FOR PROPHYLAXIS OF CHEMOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2002-12-31 | — | — | US | claimed |
| EP-1161232-A4 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-09-18 | — | — | EP | claimed |
| EP-1161232-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2001-12-12 | — | — | EP | claimed |
| WO-2000035442-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-22 | — | — | WO | claimed |
| EP-1161232-B1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2004-03-24 | — | — | EP | disclosed |
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2003-06-12 | — | — | US | disclosed |
| US-6500863-B1 | INTERLEUKIN BINDING INHIBITORS SUCH AS N-(2-HYDROXYL-3-AMINO SULFONYL-4-CHLOROPHENYL)-N'-(2-BROMOPHENYL)UREA, USED FOR PROPHYLAXIS OF CHEMOKINE MEDIATED DISEASES | SMITHKLINE BEECHAM CORPORATION | 2002-12-31 | — | — | US | disclosed |
| EP-1161232-A4 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2002-09-18 | — | — | EP | disclosed |
| EP-1161232-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SmithKline Beecham Corporation (US) | 2001-12-12 | — | — | EP | disclosed |
| WO-2000035442-A1 | HYDROXY DIPHENYL UREA SULFONAMIDES AS IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109527-A1 | Hydroxy diphenyl urea sulfonamides as IL-8 receptor antagonists | CXCL8, CCR8, IL18 | ALDH1A1 1321/4885TSHR 1480/4885CXCR2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.